TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Modulating Effects of Oil Palm Phenolics in Uncontrolled Insulin-treated Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is currently injecting an insulin dosage of \>= 1.0 unit/kilogram/day.~* Subject has a serum glycosylated haemoglobin (HbA1c) \>= 9.~* Subject has fasting plasma glucose level of more than 7.0 mmol/L and less than 12.0 mmol/L.~* Subjects or his/her legally acceptable representative is willing to provide written informed consent.~Exclusion Criteria:~* Subject with diabetic ketoacidosis or in coma.~* Subject with terminal cancer.~* Subject with renal failure (serum creatinine more than 200 umol/L).~* Subject with significant liver impairment (liver function test of 5 times more than the upper limit level).~* Subject with severe dementia and psychosis.~* Subject requires of long term corticosteroid treatment for the underlying disease such as connective tissue disorder.~* Subject with hemoglobinopathy or anemia.~* Subject underwent splenectomy or suffered from splenomegaly.~* Subject with chronic substance abuse such as chronic alcoholism or chronic opiate usage.~* Female subject of childbearing potential unless subject underwent bilateral tubal ligation, bilateral oophorectomy or hysterectomy previously.~* Subject or care giver is unable to perform self-monitoring of capillary blood glucose at home.~* Subject who have been included in any other clinical trial within the previous 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Oil Palm Phenolics (Type: EXPERIMENTAL): 500 mg gallic acid equivalent (GAE), twice daily, 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* NINCDS/ADRDA criteria for probable AD~* MMSE between 12-26~* Treatment with a cholinesterase inhibitor or an NMDA (N-methyl-D-asparate) antagonist with stable dose for at least 12 weeks~* Home monitoring available for supervision of medications~* Caregiver available to accompany patient to all visits and willing to participate in study as informant~* Fluent in English or Spanish~* Medical stability for this study as confirmed by review of records, internist's physical exam, neurological exam, and laboratory tests~* Stable doses of non-excluded medication~* No evidence of hepatic insufficiency~* Able to swallow oral medications~* Ability to participate in the informed consent process~Exclusion Criteria:~* History of hypotension or unstable hypertension~* Active hepatic or renal disease~* Use of another investigational drug within the past two months~* History of clinically significant stroke~* History of seizure or head trauma with disturbance of consciousness within the past two years~* Major mental illness including psychotic disorders, bipolar disorder, or major depressive episode that is not in remission for less than 12 months~* Women of child-bearing age unless using effective birth control or at least one year post-menopausal or surgically menopausal~* Any ferrous or metallic materials which are contraindicated for MRI~Medication Exclusions~* Current use of drugs with significant anticholinergic or antihistaminic properties

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Meganatural-Az Grapeseed Extract (Type: ACTIVE_COMPARATOR): Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day
- Placebo (Type: PLACEBO_COMPARATOR): Subjects receive capsules identical in appearance to the active agent with the same incremental schedule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vortioxetine to Prevent Return of Symptoms in Children With Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~De novo participants~* The participant has a primary diagnosis of MDD according to DSM-5™ although co-morbid anxiety disorders will be permitted (except Post Traumatic Stress Disorder (PTSD) and Obsessive Compulsive Disorder (OCD)).~* The participant has a CDRS-R total score ≥45 at the Screening and Baseline Visits.~* The participant has a Clinical Global Impression - Severity of Illness (CGI-S) ≥4 at the Screening and Baseline Visit~Exclusion Criteria:~* The participant receives ongoing current psychotherapy that is planned to be intensified. Interpersonal psychotherapy (IPT) or cognitive behavioural therapy (CBT) are not allowed.~* The participant presents with, or has a history of, an Axis I (DSM-5TM) diagnosis of Bipolar Disorder, PTSD, OCD, Autism, Pervasive Developmental Disorder (PDD), or Schizophrenia or Schizoaffective Disorder.~* The participant has a diagnosis of attention-deficit/hyperactivity disorder (ADHD) and is not maintained on a stable dose of a methylphenidate or amphetamine for a minimum of 4 weeks prior to the study treatment.~* The participant has attempted suicide or is at significant risk of suicide~Other inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Vortioxetine -open label treatment period (Type: EXPERIMENTAL): Vortioxetine - 5, 10, 15, and 20 mg/day, film-coated tablets, orally once daily.~Patients will receive a targeted dose of 10 mg/day vortioxetine, however the investigator has the possibility to adjust the dose in case of unsatisfactory response or in case of dose-limiting adverse events.
- Vortioxetine -double-blind relapse prevention period (Type: EXPERIMENTAL): Vortioxetine - 5, 10, 15, and 20 mg/day, encapsulated film-coated tables, orally once daily.~In the double-blind period, the patients will continue on the same fixed dose as during the end of the open label period
- Placebo -double-blind relapse prevention period (Type: PLACEBO_COMPARATOR): Placebo - encapsulated tablets, orally once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Propofol Dosing for (Preterm) Newborn Infants That Need Endotracheal Intubation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~All neonates admitted to the two participating intensive care units:~* Less than 28 days postnatal age~* Who need endotracheal intubation~Exclusion Criteria:~Patients with:~* Major congenital anomalies or neurological disorders,~* Neonates with an abnormal upper airway,~* Those receiving continuous sedatives or opioids, and~* Those whose mothers received sedatives or opioids before or during delivery will be excluded during the first 2 days of life.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 28 Days
- Healthy Volunteers: f

Study Arms:
- Propofol (Type: EXPERIMENTAL): A predetermined propofol dose is used in every 5 consecutive patients per age group. Starting dose is 1.0 mg/kg. Dose is increased or decreased with 0.5 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~* Enrolled on another LPD protocol.~* Weight greater than or equal to 25 kg~* Willingness to participate~EXCLUSION CRITERIA:~* Age less than 7 years~* Weight less than 25 kg~* Cardiovascular instability~* Hct less than 30~* Inadequate venous access~* PTT or PT greater than 1.5 normal~* Pregnancy~* Women who are actively breastfeeding~* Other condition which the attending physician or Apheresis Unit staff considers a contraindication to the procedure~* For Hetastarch procedure~  * Hypertension~ * Evidence of fluid retention

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Donors first admitted to another approved clinical research protocol of the NIAID before having the apheresis procedures described in this protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 (or as required by local regulation).~* Histological or cytological confirmation of advanced/metastatic ALK+ NSCLC.~* Pretreated with up to three prior lines of an ALK TKI treatment, including at least one prior line of a second or third-generation ALK TKI (alectinib, brigatinib, ensartinib, or lorlatinib) in Phase 1.~* ECOG performance status ≤ 1.~* Existence of measurable or evaluable disease (according to Response evaluation criteria in solid tumors \[RECIST v1.1\] criteria).~* Subjects with asymptomatic CNS metastases and/or asymptomatic leptomeningeal carcinomatosis are eligible.~* Adequate organ function.~Exclusion Criteria:~* Major surgery within four weeks of the start of TPX-0131 treatment.~* Clinically significant cardiovascular disease~* Any of the following cardiac criteria:~  * Mean resting corrected QT interval (QTc) \> 470 msec obtained from three ECGs and any factors that increase the risk of QTc prolongation or arrhythmic events~ * Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG~* Known clinically significant active infections not controlled with systemic treatment (bacterial, fungal, viral including HIV positivity).~* Gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.~* Subjects being treated with or anticipating the need for treatment with strong CYP3A4 inhibitors or inducers.~* Subjects with current or anticipated need for drugs that are sensitive CYP2C9 substrates with narrow therapeutic indices.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TPX-0131 (Type: EXPERIMENTAL): The Phase 1 part of the study will determine the safety, tolerability, PK, MTD, and RP2D of TPX-0131.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Immediate Postplacental IUD Insertion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* 18 yo or older~* Singleton pregnancy at ≥32 weeks gestation at time of enrollment~* Voluntarily requesting either copper T380A or levonorgestrel IUD (LNG-IUS) placement for postpartum contraception~* English or Spanish speaking~* Able to give consent and agree to the terms of the study~* Less than 10 prenatal visits or 2 or more no show visits~* Since IUDs are not on our hospital formulary, the patient must qualify for a Long Acting Reversible Contraceptive (LARC) IUD (this includes all Oregon Health Plan (OHP) or Citizen/Alien Waived Emergent Medical (CAWEM) insured patients or women with income \<300% of the federal poverty line).~Exclusion Criteria:~* Anatomic uterine abnormalities that prevent proper fundal placement of IUD (obstructive myomata, bicornuate, septate, etc)~* Chorioamnionitis (also consider other risk factors such as prolonged rupture of membranes \>18 hours, prolonged labor \>24 hours, fever \>38C)~* Puerperal sepsis~* Unresolved postpartum hemorrhage~* Extensive genital trauma~* Current incarceration~* Known or suspected untreated endocervical gonorrhea, chlamydia~* Wilson's disease, copper allergy (Paragard only)~* Known or suspected cervical or endometrial cancer or pelvic tuberculosis~* Current breast cancer (LNG-IUS only)~* Systemic lupus erythematosus (SLE) with severe thrombocytopenia (Paragard only)~* Trophoblastic disease (benign or malignant)~* AIDS not stable on antiretroviral

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Immediate postplacental IUD insertion (Type: EXPERIMENTAL): Women randomized to the immediate postplacental IUD group will receive their IUD within 60 minutes of placental delivery.
- 6 weeks postpartum IUD insertion (Type: ACTIVE_COMPARATOR): Subjects who are randomized for IUD insertion at their postpartum visit will be assisted in scheduling a postpartum visit and IUD placement with their usual obstetrical care provider.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed non-small cell lung cancer~* Tumor between 1 cm and 6 cm~* No evidence of nodal involvement or distant metastases~* Deemed to be a candidate for stereotactic body radiation therapy for NSCLC~* Able to lie still during DCE-MRI (up to 60 minutes)~* Adequate renal function to tolerate intravenous gadolinium contrast injection~Exclusion Criteria:~* Prior thoracic radiotherapy or surgery~* Implanted pacemaker or cardiac defibrillator~* Contraindications to undergoing MRI~* Uncontrolled intercurrent illness~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Arm (Type: EXPERIMENTAL): Stereotactic Body Radiation Therapy: either 54 Gy in 3 fractions or 50-60 Gy in 5 fraction over a span of 15 days at most.~DCE-MRI was performed at four time points during therapy: at baseline prior to SBRT, 1-2 days after the first treatment fraction, 1-2 weeks after the end of the SBRT course, and 3 months after completing radiotherapy.~4D-CT scan 3 months after completing radiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 18 years of age or older~* Subjects scheduled for a clinically indicated CECT requiring 40 grams of iodine (125 mL)~* Subjects have an abnormal screening SCr that results in a calculated eGFR of \< 60 mL/min/1.73 m2 using the MDRD formula and acute causes for an elevation in SCr have been excluded~* Subjects have stable reduced renal function which is defined as an abnormal screening SCr measurement with a \< 15% difference from the oldest historical SCr measurement obtained within the proceeding 1 week to 12 weeks~* Subjects must provide written consent and agree to abide by the site and study requirements~Exclusion Criteria:~* Subjects previously entered into this study~* Subjects on dialysis~* Subjects received any investigational drug within 30 days of contrast administration or participated in an investigational study within 30 days prior to study enrollment~* Subjects have undergone a procedure using iodinated or gadolinium contrast agent within 7 days prior to contrast administration, or is scheduled to receive additional doses of contrast agents during the 48-72 hour post-study contrast administration~* Subjects in acute renal failure or have one or more known causes of acute renal failure~* Subjects have known or suspected unstable renal function~* Subjects scheduled for a surgical intervention or other procedure within 72 hours after the contrast administration~* Subjects taking NSAIDs (with the exception of ASA) and/or any type of diuretics who cannot discontinue these drugs post contrast administration and hold all subsequent doses until the 48-72 hour post contrast SCr has been drawn~* Subjects taking aminoglycosides~* Subjects known to have an organ transplantation~* Subjects have severe congestive heart failure (Class III-IV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Ioversol 320 mgI/mL
- 2 (Type: ACTIVE_COMPARATOR): Iodixanol 320 mgI/mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females of non-childbearing potential ≥50 years of age (at the time of signing the informed consent document) with documented IPF~* Diagnosis of IPF based on current ATS/ERS guidelines~  * Usual interstitial pneumonia (UIP) pattern on HRCT and/or UIP pattern on histopathology (ie surgical lung biopsy), and~ * Exclusion of known causes of interstitial lung disease (such as environmental exposure, connective tissue disease and drug toxicity), Or~ * UIP pattern on surgical lung biopsy required if HRCT is inconsistent with UIP~Exclusion Criteria:~* FVC : \< 50% predicted \>90% predicted~* DLco:\< 25% predicted \>90% predicted~* Saturated oxygen (SpO2) of \<92% (room air \[sea level\] at rest). SpO2 of \< 88% (room air \[≥ 5,000 feet above sea level (1524 meters\]) at rest)~* Use of any cytotoxic/immunosuppressive agent (other than prednisone ≤ 12.5 mg/day or equivalent) including, but not limited to, azathioprine, cyclophosphamide, methotrexate and cyclosporine within 4 weeks of screening~* Use of any cytokine modulators:~  * Use of any biologic agent (such as etanercept, adalimumab, efalizumab, infliximab, golimumab, certolizumab) within 12 weeks or five half-lives of screening, and in the case of rituximab, use within 24 weeks of screening or no recovery of CD 19-positive B lymphocytes if the last dose of rituximab has been more than 24 weeks prior to screening~ * Alefacept within 24 months of randomization~* Use of any therapy targeted to treat IPF (including but not limited to d-penicillamine, endothelium receptor antagonist \[eg bosentan, ambrisentan\], interferon gamma-1B, pirfenidone) within 4 weeks of screening~* Use of n-acetylcysteine (NAC) for IPF (≥1800 mg/day) within 4 weeks of screening~* Use of any investigational drug within one month of screening, or 5 PD/PK half lives, if known (whichever is longer)~* Current smoker

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): • Cohort 1: CC-930 50 mg PO daily (two 25 mg capsules once per day PO) beginning on Day 1 in the AM.
- Cohort 2 (Type: EXPERIMENTAL): • Cohort 2: CC-930 100 mg PO daily (one 100 mg capsule once per day PO) beginning on Day 1 in the AM
- Cohort 3 (Type: EXPERIMENTAL): • Cohort 3: CC-930 100 mg twice daily approximately 12 hours apart (one 100 mg capsule twice per day PO) beginning on Day 1.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Progesterone for the Prevention of Preterm Birth in Women With Arrested Preterm Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Singleton or twin gestation~* Estimated gestational age between 24 0/7 and 33 6/7 weeks' gestation~* Initially present with regular contractions and clinical diagnosis of preterm labor but remain undelivered with 1) no further cervical change 12 hours after discontinuation of acute tocolytic therapy; or 2) be considered eligible for discharge based on attending physician judgment prior to the 12 hour period of time~* The participant's cervix must be at least 1 cm at the time of enrollment~Exclusion Criteria:~* Non-English speaking~* Rupture of membranes~* Chorioamnionitis~* Non-reassuring fetal status~* Maternal indication for delivery~* Placental abruption~* Intrauterine fetal demise~* Prenatally diagnosed major fetal anomaly~* Cervical cerclage in place~* Previous administration of progesterone during the current pregnancy for a history of preterm birth or short cervix~* Participant is either unwilling or unable to attend follow-up study visits following hospital discharge

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Micronized progesterone suppository (Type: ACTIVE_COMPARATOR): Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation.
- Placebo suppository (Type: PLACEBO_COMPARATOR): One placebo suppository vaginally daily until 36 6/7 weeks' gestation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues